Home/Filings/4/0000950170-24-106915
4//SEC Filing

Cohen Joshua B 4

Accession 0000950170-24-106915

CIK 0001658551other

Filed

Sep 15, 8:00 PM ET

Accepted

Sep 16, 5:39 PM ET

Size

6.5 KB

Accession

0000950170-24-106915

Insider Transaction Report

Form 4
Period: 2024-09-12
Cohen Joshua B
DirectorCo-Chief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2024-09-12$1.57/sh+34,449$54,0853,237,301 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2024-09-1234,4491,857 total
    Exercise: $1.57Exp: 2025-02-26Common Stock (34,449 underlying)
Footnotes (1)
  • [F1]This option is fully vested and exercisable.

Documents

1 file

Issuer

Amylyx Pharmaceuticals, Inc.

CIK 0001658551

Entity typeother

Related Parties

1
  • filerCIK 0001898644

Filing Metadata

Form type
4
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 5:39 PM ET
Size
6.5 KB